Switzerland: Services Agreement Lonza and Bioqube Join Forces for Development and Manufacture of Biologics and Small Molecules
Within the framework of a five-year services agreement, Lonza and Bioqube want to provide for the development and manufacturing of biologics and small molecules for portfolio companies of Bioqube. The offering is to accelerate timelines for the development and manufacturing of molecules and disruptive technologies.
Basel/Switzerland — Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, and Lonza announced a framework agreement covering a strategic collaboration for the development and manufacturing of biologics and small molecules.
The agreement was developed to support the unique needs of the venture capital company (VC) and its portfolio companies looking to simplify the development of their molecules. Under the terms of the agreement, Lonza will support Bioqube Ventures during the due diligence of candidate biotechs and provide a tailored offering of advice and services to its portfolio companies.
The offering comprises Lonza's expertise and technology that is designed to accellarate timelines while mitigating risks of the development and manufacturing of molecules ranging from monoclonal antibodies, complex proteins, and small molecules to antibody-drug conjugates. The holistic approach to drug substance and drug product development and manufacturing across various platforms simplifies the supply chain, reduces process complexity, and allows for a shortened development timelines, the company states.